The Efficacy and Safety of Ezetimibe for Treatment of Dyslipidemia After Heart Transplantation

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 3060-3062

  Crespo Leiro, M G ^a   Paniagua, M J ^a   Marzoa, R ^a   Grille, Z ^a   Naya, C ^a   Flores, X ^a   Rodriguez, J A ^a   Mosquera, V ^a   Franco, R ^a   Castro Beiras, A ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; CYCLOSPORIN; EVEROLIMUS; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HAND EDEMA; HEART TRANSPLANTATION; HUMAN; KIDNEY DYSFUNCTION; LIVER TOXICITY; MALE; MONOTHERAPY; MYALGIA; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; DYSLIPIDEMIAS; FEMALE; HEART TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRAVASTATIN; PYRROLES; YOUNG ADULT;

EID: 55749093239     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.007     Document Type: Article

References (12)

1. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621
2. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four-year randomized trial. Circulation 96 (1997) 1398
3. Marzoa-Rivas R., Crespo-Leiro M.G., Paniagua-Marin M.J., et al. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant Proc 37 (2005) 4071
4. Langone A.J., and Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 81 (2006) 804
5. Buchanan C., Smith L., Corbett J., et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 6 (2006) 770
6. Turk T.R., Voropaeva E., Kohnle M., et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant 23 (2008) 369
7. Patel A.R., Ambrose M.S., Duffy G.A., et al. Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. J Heart Lung Transplant 26 (2007) 281
8. Lindenfeld J., Page II R.L., Zolty R., et al. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation 111 (2005) 113
9. Page II R.L., Miller G.G., and Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 111 (2005) 230
10. Chuang P., and Langone A.J. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors. Am J Ther 14 (2007) 438
11. Kohnle M., Pietruck F., Kribben A., et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 6 (2006) 205
12. Moro J., Almenar L., Martinez-Dolz L., et al. Ezetimibe in heart transplantation: initial experience. Transplant Proc 39 (2007) 2389